BioCryst Pharmaceuticals, Inc.
Head Quarters
Suite 200 4505 Emperor Boulevard USWebsite
http://www.biocryst.comIndustry
BiotechnologyEmployees
65Exchange
NASDAQBioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 1 |
| Gross Margin (%) | 0.90% |
| Net Margin (%) | -0.47% |
| Returns | Stock |
| Sales | $30.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | -$8.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 52.96 |
| EPS | $0.00 |